Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) EBT Margin (2017 - 2025)

Crinetics Pharmaceuticals has reported EBT Margin over the past 9 years, most recently at 1990.5% for Q4 2025.

  • Quarterly results put EBT Margin at 1990.5% for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was 6041.5% (up 2260855.0% YoY), and the annual figure for FY2025 was 6043.88%, up 2263158.0%.
  • EBT Margin for Q4 2025 was 1990.5% at Crinetics Pharmaceuticals, up from 90972.73% in the prior quarter.
  • Over the last five years, EBT Margin for CRNX hit a ceiling of 1074.23% in Q1 2022 and a floor of 90972.73% in Q3 2025.
  • Median EBT Margin over the past 5 years was 9400.75% (2022), compared with a mean of 15155.36%.
  • Peak annual rise in EBT Margin hit 733895bps in 2025, while the deepest fall reached -1640581bps in 2025.
  • Crinetics Pharmaceuticals' EBT Margin stood at 2857.88% in 2021, then crashed by -125bps to 6438.93% in 2022, then crashed by -153bps to 16302.89% in 2023, then fell by -14bps to 18556.89% in 2024, then surged by 89bps to 1990.5% in 2025.
  • The last three reported values for EBT Margin were 1990.5% (Q4 2025), 90972.73% (Q3 2025), and 11217.94% (Q2 2025) per Business Quant data.